On Wednesday, Grifols SA (NASDAQ:GRFS) said it ended discussions with Brookfield Capital Partners (UK) Limited about a ...

Grifols rejects Brookfield’s €10.5/share offer, signaling undervaluation. Read why GRFS stock is a strong "Buy" despite the ...

For Spain’s billionaire Grifols family, which turned a blood-collection business into one of the world’s largest medical ...

Canadian fund Brookfield said on Wednesday it has dropped its plan to take over Spain's Grifols due to a disagreement over ...

The Grifols family won’t support a new bid by a third-party to take its namesake drug-maker private amid indications that ...

Grifols (NASDAQ:GRFS) has commenced discussions with banks to refinance its bonds due in 2025, Bloomberg News reported, a day ...

Shares of Grifols GRFS lost over 7% on Wednesday after the company announced that Canada-based Brookfield Asset Management ...

Grifols (GRFS) stock dropped as Brookfield Asset Management (BAM) is reportedly withdrawing its offer to take the plasma ...

The board of Spanish plasma-based medicines producer Grifols has announced the termination of discussions with Brookfield ...

Brookfield withdrew its bid for the Spanish pharmaceutical company following a deadlock between the two side over price ...

Barcelona-based Grifols has seen its stock value plummet since January, when short seller Gotham City Research accused the company of manipulating debt and earnings reporting by consolidating profit ...